Trial Profile

Phase 3 Study to Assess Gemtuzumab, in Combination With Standard Chemotherapy, on MRD Levels, and the Role of Glasdegib as a Post-transplant Maintenance, in Adult, 18-60 Years, With Previously Untreated de Novo Fav-interm Risk AML

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 11 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gemtuzumab ozogamicin (Primary) ; Glasdegib (Primary) ; Cytarabine; Daunorubicin
Indications Acute myeloid leukaemia
Focus Therapeutic Use
Acronyms AML1819

08 Nov 2024 Planned primary completion date changed from 1 Apr 2024 to 1 Apr 2025.
09 Apr 2024 Planned primary completion date changed from 1 Apr 2023 to 1 Apr 2024.
15 Jun 2023 preliminary (n=145) results of the post-consolidation MRD analysis assessing the efficacy of gemtuzumab ozogamicin plus intensive chemotherapy in acute myeloid leukemia patients, presented at the 28th Congress of the European Haematology Association.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com